Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFaac chimeric protein targeting tissue factor

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Cocco, Emiliano ^a   Varughese, Joyce ^a   Buza, Natalia ^a   Bellone, Stefania ^a   Glasgow, Michelle ^a   Bellone, Marta ^a   Todeschini, Paola ^a   Carrara, Luisa ^a   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Pecorelli, Sergio ^b   Lockwood, Charles J ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHIMERIC PROTEIN; CHROMIUM 51; HI CON1; INTERLEUKIN 2; MESSENGER RNA; THROMBOPLASTIN; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; COMPLEMENT; HI-CON1; IMMUNOGLOBULIN G; RNA; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CELL MEMBRANE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG CYTOTOXICITY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; ADENOCARCINOMA; BIOSYNTHESIS; CYTOTOXICITY TEST; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PAPILLOMAVIRUS INFECTION; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; UTERINE CERVIX TUMOR; VIROLOGY;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INTERLEUKIN-2; KERATINOCYTES; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; RNA, NEOPLASM; THROMBOPLASTIN; UTERINE CERVICAL NEOPLASMS;

EID: 79959228027     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-263     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997, 350:535-40. 10.1016/S0140-6736(97)02250-2, 9284774.
3. Disaia PJ, Creasman WT. Cervical Cancer. Clinical Gynecologic Oncology 1997, 1-106. St. Louis: Mosby Yearbook, Inc, Disaia PJ, Creasman WT.
4. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002, 282:C947-C970.
5. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nat Med 1996, 2:209-215. 10.1038/nm0296-209, 8574967.
6. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Aca Sci USA 1999, 96:8663-8668.
7. Santin AD, Hermonat PL, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP. Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstet Gynecol 1999, 94:78-82. 10.1016/S0029-7844(99)00282-3, 10389722.
8. Goncharuk IV, Vorobjova LI, Lukyanova NY, Chekhun VF. Vascular endothelial growth factor exression in uterine cervical cancer: correlation with clinicopathologic characteristics and survival. Exp Oncol 2009, 31:179-81.
9. Ruf W. Tissue factor and PAR signaling in tumor progression. Thromb Res 2007, 120:S7-S12.
10. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Aca Sci USA 1999, 96:8161-8166.
11. Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Aca Sci USA 2000, 97:9221-9225.
12. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Aca Sci USA 2001, 98:12180-12185.
13. Waxman E, Ross JB, Laue TM, Guha A, Thiruvikraman SV, Lin TC, Konigsberg WH, Nemerson Y. Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. Biochemistry 1992, 31:3998-4003. 10.1021/bi00131a015, 1567850.
14. Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, Schoenfeld J, Lowe D, Lai J, Rancatore P, Iverson M, Lim A, Chisholm V, Kelley RF, Riederer M, Kirchhofer D. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 2001, 85:379-389.
15. Dickinson CD, Kelly CR, Ruf W. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. Proc Natl Acad Sci USA 1996, 93:14379-84. 10.1073/pnas.93.25.14379, 26140, 8962059.
16. Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J Virol 2009, 83:6779-89. 10.1128/JVI.02443-08, 2698533, 19386711.
17. Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer 2010, 103:812-9. 10.1038/sj.bjc.6605760, 20700124.
18. Alessi P, Ebbinghaus C, Neri D. Molecular targeting of angiogenesis. Biochim Biophys Acta 2004, 4:39-49.
19. Veras E, Srodon M, Neijstrom ES, Ronnett BM. Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau Syndrome): clinicopathologic characteristics of 2 cases. Int J Gynecol Pathol 2009, 28:134-9. 10.1097/PGP.0b013e318186a83b, 19188822.
20. Simon NL, Orr JW, Hatch KD, et al. Lower extremity edema due to deep vein thrombosis in patients with recurrent cervix cancer. Gynecol Oncol 1984, 19:30-3. 10.1016/0090-8258(84)90154-9, 6205944.
21. Mohammed S, Khodadoust K. Carcinoma of the cervix causing massive intracardiac embolus. Gynecol Oncol 1995, 56:294-7. 10.1006/gyno.1995.1049, 7896201.
22. Barbera L, Thomas G. Venous thromboembolism in cervical cancer. Lancet Oncol 2008, 9:54-60. 10.1016/S1470-2045(07)70409-6, 18177817.
23. Satoh T, Oki A, Uno K, Sakurai M, Ochi H, Okada S, Minami R, Matsumoto K, Tanaka YO, Tsunoda H, Homma S, Yoshikawa H. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer 2007, 97:1053-7. 10.1038/sj.bjc.6603989, 2360447, 17895896.
24. Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006, 32:54-70. 10.1055/s-2006-933341, 16479463.
25. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992, 89:11832-11836. 10.1073/pnas.89.24.11832, 50651, 1465406.
26. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 2005, 105:1734-1741. 10.1182/blood-2004-05-2042, 15494427.
27. Monk BJ, Willmott LJ, Sumner DA. Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 2010, 116:181-6. 10.1016/j.ygyno.2009.09.033, 19861227.
28. Ortaldo JR, Woodhouse CS, Morgan AC, Herberman RB, Cheresh DA, Reisfeld RA. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol 1987, 138:3566-3572.
29. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Med 2000, 6:443-446. 10.1038/74704, 10742152.
30. Fehniger TA, Bluman EM, Porter MM, Mrozek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest 2000, 106:117-124. 10.1172/JCI6218, 314354, 10880055.
31. Caron PC, Lai LT, Scheinberg DA. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res 1995, 1:63-70.
32. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006, 100:469-78. 10.1016/j.ygyno.2005.09.040, 16249018.
33. Fiander A, Adams M, Evans AS, Bennett AJ, Borysiewicz LK. Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patients. Int J Gynecol Oncol 1995, 5:438-42.
34. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S, et al. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 2000, 48:997-1006. 10.1016/S0360-3016(00)00769-0, 11072156.
35. Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman JJ, et al. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10. Int J Radiat Oncol Biol Phys 2002, 54:1345-55. 10.1016/S0360-3016(02)03757-4, 12459356.